Prosiectau (1337)

The Determinants of University Spinout Formation and Survival: The UK Context of Network, Investment, and Management Team Effects  (01.10.2012  -  29.09.2017)

The Impossible, Powerful Spaces of BBC Radio Adaptation  (01.10.2015  -  30.11.2020)

The Low Temperature Formation of Cyclohexane Diol from Cyclohexene Utilising Green Oxidation Procedures  (01.09.2017  -  30.10.2020)

Theoretical and Computational Modelling of Compressible and Nonisothermal Viscoelastic Fluids  (01.09.2014  -  31.01.2019)

The Selective Oxidation of Bio-derived Platform Chemicals over Supported Gold Catalysts  (01.10.2012  -  31.03.2016)

The UK Catalysis Hub  (01.06.2013  -  30.11.2018)

Towards a Semantic Web of Things for Smart Cities  (01.07.2013  -  30.06.2017)

T1D-Plus: a clinical trial platform for combined beta cell preservation therapy  (01.09.2022  -  31.08.2026)

T1D-Plus: An adaptive trial platform for the study of combination therapies in new-onset T1D  (01.12.2023  -  30.11.2026)

T1D UK Clinical Trials consortium - mechanistic core  (01.01.2015  -  05.12.2021)

T1D UK Immunotherapy Consortium: Clinical Engagement and Training (CET) Core  (01.05.2015  -  30.03.2020)

Tackling epidemic threats byadvancing the science of humaninteractions and infection  (01.09.2024  -  31.05.2025)

Tackling Radicalisation in Dispersed Societies  (01.08.2012  -  31.07.2015)

TACTICC study  (01.06.2015  -  31.12.2016)

Taffs Well Thermal Spring - Heat recovery  (14.10.2019  -  30.03.2020)

Tai Ffres Research and Evaluation  (01.02.2023  -  31.07.2024)

Tailored OligoG in the treatment of chronic infectious biofilms  (27.11.2013  -  30.06.2017)

Tailored quantum structures  (01.06.2013  -  31.05.2015)

Taith Mobility Programme  (01.09.2022  -  31.08.2025)

Take home naloxone Intervention Multi centre Emergency setting feasibility trial (TIME)  (01.03.2018  -  31.08.2020)

Taking registered reports to the next level  (01.10.2020  -  30.09.2023)

Talking about HPV related cancer: Development and testing of scripted consultations  (01.07.2014  -  30.06.2016)

Talking changes: Developing best practice in co-producing well-being outcomes with looked-after children in Wales  (01.10.2017  -  27.06.2022)

Talking Trials: Exploration of clinical trial perceptions amongst BAME communities  (01.04.2020  -  31.03.2022)

Talking Trials: Participatory approaches to creating community dialogue  (01.10.2022  -  31.01.2024)

Talk Relationships Young Persons Participation Toolkit  (01.11.2024  -  28.02.2025)

Talybont Taste & Odour Event (summer 2024):Data review and research gaps  (16.01.2025  -  15.07.2025)

Tamil temple towns: Conservation and contestation  (14.02.2018  -  28.05.2023)

Tangible Interfaces for Assiting Young People with Neurodiversity Towards better Understanding Online Harms  (01.01.2024  -  31.12.2026)

Tanzanian Onshore Palaeogene Integrated Coring  (01.06.2014  -  31.05.2015)

TAP Centre  (01.01.2020  -  31.12.2022)

TAPERS study Excess Treatment Costs  (01.10.2018  -  31.01.2022)

Targeted drug delivery to the cornea of the eye via medicated contact lenses and mucoadhesive thin films  (01.02.2019  -  28.12.2022)

Targeted drug delivery to the cornea of the eye via thin-film slow release technology  (01.05.2017  -  31.08.2018)

Targeted metabolic inhibition of T-lymphocytes: Directing immunity during human disease  (01.10.2016  -  15.11.2018)

Targeted stabilisation of human cardiac ryanodine receptors as a therapeutic strategy for cardiac disease  (01.10.2009  -  30.09.2014)

Targeted vaccines for infectious disease and cancer  (01.04.2010  -  30.09.2010)

Targeted vaccines for infectious disease and cancer  (31.03.2010  -  30.09.2012)

Targeting alpha-beta - crystalline (CRYAB): A novel strategy to impede triple-negative breast cancer development  (01.07.2014  -  31.01.2016)

Targeting aquaporins function with organometallics: New tools in chemical biology and cancer therapeutics  (01.04.2017  -  30.04.2020)

Targeting cartilage regeneration in joint and intervertebral disc diseases  (01.03.2015  -  28.02.2019)

Targeting CD200 signalling to overcome cell carcinoma immune evasion  (01.01.2014  -  31.07.2017)

Targeting CD8 using “blocking anti CD8 antibodies” as a strategy to disable autoreactive CD8+ T-cells in Type 1 diabetes  (01.01.2023  -  29.02.2024)

Targeting CLL cell survival and proliferation with bioactive cell penetrating peptides  (01.10.2010  -  30.04.2014)

Targeting common mechanisms of pathogenesis in diseases of sterol homeostasis associated with lysosome dysfunction development of novel and rapidly translatable clinical therapies (STEROLOSOM)   (01.06.2012  -  31.05.2014)

Targeting complement to treat fatty liver disease  (01.10.2022  -  30.09.2025)

Targeting Coronaviruses through Fc-dependent Antibody Activities  (01.03.2025  -  29.02.2028)

Targeting CtIP to sensitise cancer cells to DNA-damaging agents  (01.11.2016  -  31.03.2018)

Targeting ERK signalling to ameliorate intellectual disability and autism spectrum disorder associated with chromosomal rearrangements at 16p11.2  (01.11.2019  -  31.10.2025)

Targeting ERK signalling to emeliorate intellectual disability and autism spectrum disorder associated with chromosomal rearrangements at 16p11.2  (01.11.2019  -  31.10.2025)

Targeting ERK signalling to emeliorate intellectual disability and autism spectrum disorder associated with chromosomal rearrangements at 16p11.2  (01.11.2019  -  31.10.2025)

Targeting glucose metabolism for the treatment of Birt Hogg Dube Syndrome  (01.10.2009  -  30.09.2010)

Targeting G-quadruplex nucleic acid structures with caffeine gold compounds for cancer treatment  (01.10.2016  -  22.12.2017)

Targeting islet-specific CD8 Tcells in Type 1 diabetes  (01.06.2015  -  31.01.2019)

Targeting long-term responses to chemotherapy through a novel stem/immune-related vulnerability in triple negative breast cancer  (23.03.2023  -  22.03.2026)

Targeting NAD+ for retinal ganglion cell protection in experimental glaucoma  (01.10.2019  -  30.12.2022)

Targeting natural products to counter the challenge of MRSA  (01.10.2014  -  30.09.2017)

Targeting neuroinflammation in mTORC1 driven brain tumours  (01.10.2019  -  31.05.2023)

Targeting neuroinflammation: Investigating disease mechanisms, and natural protective disease mechanisms to develop therapeutic interventions  (01.04.2025  -  31.03.2028)

Targeting NF-xB activation and proliferation signals in CLL  (01.11.2013  -  31.07.2018)

Targeting of interleukin-13 receptor (IL-13R) a2 expressing pancreatic cancer by a novel hybrid lytic peptide drug  (01.10.2016  -  15.11.2018)

Targeting Ref1/STAT3 to treat Tuberous Sclerosis  (01.04.2018  -  09.02.2023)

Targeting the allosteric control of alarmone synthetases to tackle bacteria persistence  (01.10.2017  -  15.01.2020)

Targeting the CD8 coreceptor as a novel strategy for the treatment of type 1 diabetes  (01.01.2013  -  31.12.2013)

Targeting the early endosome as a therapeutic strategy in neurodegenerative diseases  (01.01.2024  -  14.04.2027)

Targeting the pathological pathways to Parkinson's  (02.05.2018  -  01.08.2021)

Targeting the terminal pathway in complement - driven disease  (30.06.2018  -  30.09.2018)

Targeting the terminal pathway in complement-driven disease  (01.10.2016  -  30.09.2018)

Targeting the Wnt receptor frizzled-7 for the treatment of gastric cancer  (01.09.2018  -  31.08.2021)

Targeting tissue macrophage generation during inflammation as a mechanism to modulate the resolution of inflammation  (31.07.2012  -  30.07.2015)

Targeting Wnt signaling to treat metastatic prostate cancer  (01.09.2021  -  31.07.2025)

Targeting zinc signalling to prevent cell division in cancer  (01.10.2016  -  30.09.2018)

Targets for treatment in AML: discovery and translation  (20.09.2015  -  23.08.2019)

Targets for treatment in AML: Discovery and translation  (01.04.2010  -  19.09.2013)

Targets for treatment in AML: Discovery and translation  (20.09.2013  -  01.12.2015)

Target temperature management after cardiac arrest  (01.04.2011  -  31.12.2013)

Targetting zinc signalling to prevent cell division in cancer  (01.10.2015  -  30.09.2018)

Target validation and lead identification in osteoarthritis  (01.12.2011  -  30.11.2013)

Target validation, indication selection/prioritisation, review of pre-clinical validation efforts and overall strategy  (08.08.2016  -  18.09.2019)

Target validation laboratories suite in the Medicine Discovery Institute  (01.10.2019  -  31.10.2020)

Tarquinia  (01.04.2022  -  31.12.2022)

Task-related Training in Huntington's Disease: A home-based intervention study  (01.06.2012  -  01.05.2014)

Taste and Odour Predictive Modelling Project  (01.10.2020  -  30.09.2021)

Taster for clinicians  (10.08.2015  -  04.10.2015)

Taverns, locals and street corners: Cross chronological studies in community drinking, regulation and public space  (01.02.2012  -  31.01.2013)

TBI-REPORTER (UK-TBI REpository and data PORTal Enabling discoveRy)  (01.10.2023  -  30.09.2028)

T cell correlates of successful immunotherapy  (01.10.2015  -  30.09.2018)

T-cell correlates of successful immunotherapy  (01.10.2016  -  30.09.2020)

T cell cross-reactivity  (09.05.2018  -  18.02.2019)

T-cell cross-reactivity causes Type 1 diabetes  (01.07.2015  -  31.10.2016)

T cell receptor repertoire of insulin reactive CD8 T cells  (01.10.2011  -  30.09.2014)

T-cell receptors for cancer immunotherapy  (01.10.2012  -  30.09.2015)

T cells, monocytes and neutrophils: Detrimental crosstalk in peritoneal dialysis-related infection.  (01.04.2009  -  31.03.2013)

Teacher research project  (31.03.2018  -  31.03.2019)

Teacher research project  (31.03.2018  -  31.03.2019)

Teacher training incentives in Wales, incentives in other professions  (08.02.2019  -  24.05.2019)

Teaching and learning issues in the disciplines  (01.06.2015  -  31.07.2015)

Teaching and learning resource for social workers in Wales  (01.10.2009  -  31.08.2010)